Online Personal Training in Patients with Marfan Syndrome: A Randomized Controlled Study of its Impact on Quality of Life and Physical Capacity

Steeve Jouini; Olivier Milleron; Ludivine Eliahou; Guillaume Jondeau; Damien Vitiello

doi:10.1101/2023.05.16.23289922

Abstract

Background Marfan syndrome (MFS) is a rare genetic disorder affecting the vascular and musculoskeletal systems. Exercise is classically contraindicated and there are no data on the limitations associated with the syndrome and the benefits of training in this population. This study aimed to characterise the quality of life (QoL) and physical capacity of patients with MFS and to evaluate the benefits of a 3-month online personal training program.

Methods MFS patients were compared with healthy subjects (H-S) at baseline. They were then randomized 1:1 into a training group (MFS-T) and a control group (MFS-C). The training consisted of 2 supervised online training sessions per week at home for 3 months, and the session program was selected based on the initial assessment. The main outcome measure was QoL as assessed by the MOS SF-36. The evolution of parameters during training was compared between MFS-T and MFS-C.

Results At baseline, QoL in all dimensions was lower in MFS. Peak oxygen uptake (VDO₂peak) was also 25% lower, as was muscle elasticity. Training significantly improved 1) QoL (+20.2±14.3 MFS-T vs. 0.7±0.5 MFS-C), 2) VDO₂peak (+34% MFS-T vs. 14% MFS-C), 3) muscle elasticity index (11.5±8.2 MFS-T vs. +1.2±1. 7 MFS-C), reduced blood pressures during isometric squat (systolic −19±30 MFS-T vs. 0±6 MFS-C; diastolic −27±39 MFS-T vs. +2±15 MFS-C), reduced pulse wave velocity (PWV) at rest (-1.20±1.89 MFS-T vs. −0.40±1.61 MFS-C) and after peak exercise (-0.42±0.45 MFS-T vs. 0.08±0.48 MFS-C). Aorta diameter remained stable in both groups (MFS-T −0.19±1.1 vs. 0.11±0.78 MFS-C). After training, QoL remained lower in MFS-T than in H-S, but peak VDO₂, PWV at rest and after exercise were similar to those of H-S.

Conclusions A 3-month online training program had a beneficial effect on QoL, cardiovascular and muscular parameters in MFS without affecting aortic root diameter.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04553094

Funding Statement

The study was sponsored by the Marfan Association, Multi-Fava, and Avenir Foundation. The investigation was conducted by an independent commission, at the request of the Committee for the Protection of Persons (CPP) ID-RCB Number: 2020-A00057-32. And the monitoring committee of the French Society of Cardiology.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Comite de protection des personnes (CPP) SUD MEDITERRANNE CHU HOPITAL DE CIMIEZ CS 91179 06003 NICE CEDEX 1 TELEPHONE : 0492034409 E-MAIL : cppsudmditerraneev{at}chu-nice.fr site internet : http://cpp-sud-mediterrannee-v.fr AVIS FAVORABLE (positive review)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data generated or analyzed during this study are included in this published article and its supplementary information files. Detailed data that support the findings of this study will be available.

Non-standard abbreviations and acronyms

1RM: One repetition maximum
MFS: Marfan syndrome
FBN1: Fibrillin-1
MFS-C: Marfan syndrome control
MFS-T: Marfan syndrome training
H-S: Healthy subjects
FB: Fat body
MM: Mass muscular
BMI: Body mass index
EF: Ejection fraction
LV: Left ventricle
GLS: Global longitudinal strain
RV: Right ventricle
PWV: Pulse wave velocity
OUES: Oxygen uptake efficiency slope
VDO₂peak: Peak oxygen uptake
VT1: First ventilatory threshold
VE: Minute ventilation
VDCO₂: Volume of CO₂ produced per minute
VE/VDCO₂: Ventilation/carbon dioxide output ratio
FEV1: Forced expiratory volume in one second
mET: Muscular exercise testing
HR: Heart rate
SBP: Systolic blood pressure
DBP: Diastolic blood pressure
CPET: Cardiopulmonary exercise testing
Aix: Augmentation index
TGF-B: Transforming growth factor beta
TIMP: Tissue inhibitors of metalloproteinases
MMPs: Matrix metalloproteinases
QoL: Quality of life

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.